Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Charcot-Marie-Tooth disease
Biotech
NMD accelerates rare disease asset despite primary endpoint miss
With patients improving on multiple secondary endpoints, the biotech is accelerating development of the drug candidate.
Nick Paul Taylor
Feb 3, 2026 4:30am
Applied Tx's stock drops on non-update for rare disease asset
Sep 29, 2025 10:57am
Applied's rare disease drug suffers another phase 3 failure
May 19, 2025 7:20am
Pharnext blames ‘unexpected’ placebo results for phase 3 failure
Dec 11, 2023 9:18am
Acceleron ditches midstage drug after flop
Mar 10, 2020 7:20am
Neurogene nets $68.5M to advance therapies for neuro diseases
Feb 12, 2019 7:47am
